Abstract
The present study was designed to assess the clinical characteristics and outcomes of metaplastic breast cancer (MBC) compared to general invasive ductal carcinoma (IDC) and the triple-negative subtype (TN-IDC). The study population included 35 MBC and 2,839 IDC patients, including 473 TN-IDC diagnoses, from the National Cancer Center, Korea between 2001 and 2008. The clinicopathological characteristics and clinical outcomes were retrospectively reviewed. Mean age of patients was 47.4 years for the MBC group and 48.3 years for the IDC group. The MBC patients presented with a larger tumor size (≥T2, 74.3% vs. 38.8%, P < 0.001), more distant metastasis at the first diagnosis (8.6% vs. 2.0%, P = 0.04), higher histologic grade (grade 3, 65.7% vs. 41.4%, P < 0.001), fewer estrogen receptor (ER), and progesterone receptor (PgR) positivity (ER+, 5.7% vs. 65.4%, P < 0.001; PgR+, 8.6% vs. 55.8%, P < 0.001), higher Ki-67 expression (35.5 ± 26.2% vs. 20.6 ± 19.8%, P = 0.024), and more TN subtypes (80.0% vs. 16.7%, P < 0.001) compared to the IDC group. Fifteen (46.8%) MBC patients and 260 (9.3%) IDC patients experienced disease recurrence with a median follow-up of 47.2 months (range 4.9–100.6 months). MBC was a poor prognostic factor for disease recurrence and overall survival in univariate and multivariate analysis (HR 3.89 in recurrence, 95% CI: 1.36–11.14, P = 0.01; HR 5.29 in death, 95% CI: 2.15–13.01, P < 0.001). MBC patients also experienced more disease recurrence (HR 3.99, 95% CI: 1.31–12.19, P = 0.01) and poorer overall survival (HR 3.14, 95% CI: 1.19–8.29, P = 0.02) compared to the 473 TN-IDC patients, as reflected by aggressive pathological features. Patients with MBC appeared to have inherently aggressive tumor biology with poorer clinical outcomes than those with general IDC or TN-IDC.
Similar content being viewed by others
References
Schnitt SJ, Guidi AJ (2000) Pathology of invasive breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the breast, 2nd edn. Lippincott, Williams and Wilkins, Philadelphia, pp 440–443
Oberman HA (1987) Metaplastic carcinoma of the breast. A clinicopathologic study of 29 patients. Am J Surg Pathol 11:918–929
Gunhan-Bilgen I, Memis A, Ustun EE, Zekioglu O, Ozdemir N (2002) Metaplastic carcinoma of the breast: clinical, mammographic, and sonographic findings with histopathologic correlation. Am J Roentgenol 178:1421–1425
Wargotz ES, Norris HJ (1990) Metaplastic carcinomas of the breast: V. Metaplastic carcinoma with osteoclastic giant cells. Hum Pathol 21:1142–1150
Wargotz ES, Norris HJ (1990) Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin. Cancer 65:272–276
Wargotz ES, Deos PH, Norris HJ (1989) Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum Pathol 20:732–740
Wargotz ES, Norris HJ (1989) Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum Pathol 20:628–635
Carter MR, Hornick JL, Lester S, Fletcher CD (2006) Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am J Surg Pathol 30:300–309
Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN (1999) Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol 10:413–419
Brenner RJ, Turner RR, Schiller V, Arndt RD, Giuliano A (1998) Metaplastic carcinoma of the breast: report of three cases. Cancer 82:1082–1087
Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K (2007) Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol 14:166–173
Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752
Sorlie T (2004) Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 40:2667–2675
Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657
Carey LA, Dees EC, Sawyer L et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329–2334
Nam BH, Kim SY, Han HS et al (2008) Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 10:R20
McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180–1184
Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. Springer, New York
Henson DE, Ries L, Freedman LS, Carriaga M (1991) Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 68:2142–2149
Tomasello G, de Azambuja E, Dinh P et al (2008) Jumping higher: is it still possible? The ALTTO trial challenge. Expert Rev Anticancer Ther 8:1883–1890
Moy B, Goss PE (2007) TEACH: Tykerb evaluation after chemotherapy. Clin Breast Cancer 7:489–492
Chao TC, Wang CS, Chen SC, Chen MF (1999) Metaplastic carcinomas of the breast. J Surg Oncol 71:220–225
Dave G, Cosmatos H, Do T, Lodin K, Varshney D (2006) Metaplastic carcinoma of the breast: a retrospective review. Int J Radiat Oncol Biol Phys 64:771–775
Chhieng C, Cranor M, Lesser ME, Rosen PP (1998) Metaplastic carcinoma of the breast with osteocartilaginous heterologous elements. Am J Surg Pathol 22:188–194
Wargotz ES, Norris HJ (1989) Metaplastic carcinomas of the breast. III. Carcinosarcoma. Cancer 64:1490–1499
Luini A, Aguilar M, Gatti G et al (2007) Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat 101:349–353
Lien HC, Hsiao YH, Lin YS et al (2007) Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene 26:7859–7871
Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K et al (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69:4116–4124
Acknowledgment
This study was supported in part by NCC Grant 0610240.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Jung, SY., Kim, H.Y., Nam, BH. et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat 120, 627–637 (2010). https://doi.org/10.1007/s10549-010-0780-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-010-0780-8